Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Sep 1;29(9):1001-1004.
doi: 10.1097/GME.0000000000002057. Epub 2022 Aug 23.

Reassuring data regarding the use of hormone therapy at menopause and risk of breast cancer

JoAnn V Pinkerton  1 , Carolyn S Wilson  1 , Andrew M Kaunitz  2
Affiliations
Editorial

Reassuring data regarding the use of hormone therapy at menopause and risk of breast cancer

JoAnn V Pinkerton et al. Menopause. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Financial disclosure/conflicts of interest: J.V.P. reports participating in a multicenter clinical trial on nonhormone therapy for hot flashes, for which the University of Virginia received financial support from Bayer. A.M.K. reports that his institution receives financial support from Merck and Bayer for ongoing clinical trials. C.S.W. has nothing to disclose.

Comment on

References

    1. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women's health initiative randomized controlled trial. JAMA 2004;291:1701–1712. doi: 10.1001/jama.291.14.1701 - DOI
    1. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast, cancer and mammography in healthy postmenopausal women: the women's health initiative randomized trial. JAMA 2003;289:3243–3253. doi: 10.1001/jama.289.24.3243 - DOI
    1. Chlebowski RT, Rohan TE, Manson JE, et al. Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 women's health initiative randomized clinical trials. JAMA Oncol 2015;1:296–305. doi: 10.1001/jamaoncol.2015.0494 - DOI
    1. Pan K, Lavasani S, Aragaki AK, Chlebowski RT. Estrogen therapy and breast cancer in randomized clinical trials: a narrative review. Menopause 2022;29:1086–1092. doi: 10.1097/GME.0000000000002021 - DOI
    1. Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. JAMA 2020;324:369–380. doi: 10.1001/jama.2020.9482 - DOI